924 related articles for article (PubMed ID: 17612779)
1. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
2. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
[TBL] [Abstract][Full Text] [Related]
3. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
[TBL] [Abstract][Full Text] [Related]
4. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
[TBL] [Abstract][Full Text] [Related]
5. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
[TBL] [Abstract][Full Text] [Related]
6. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
8. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
10. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Ste-Marie LG; Sod E; Johnson T; Chines A
Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
13. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
[TBL] [Abstract][Full Text] [Related]
14. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
Karadag-Saygi E; Akyuz G; Bizargity P; Ay P
Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
16. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
17. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
18. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
19. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
[TBL] [Abstract][Full Text] [Related]
20. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Heaney RP; Zizic TM; Fogelman I; Olszynski WP; Geusens P; Kasibhatla C; Alsayed N; Isaia G; Davie MW; Chesnut CH
Osteoporos Int; 2002; 13(6):501-5. PubMed ID: 12107665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
